All procedures were performed according to standard techniques, and all decisions concerning the strategy to be used were made by an experienced interventional cardiologist Received April 9, 2009; revised manuscript received July 7, 2009; accepted July 24, 2009 The efficacy of drug-eluting stents after rotational atherectomy (ROTA) has not been clarified.
alcified lesions have been reported to cause poor outcomes after percutaneous coronary angioplasty, presenting as major dissection 1 and low compliance. 2 Recent advances in catheter-based technology have enabled interventional cardiologists to deploy devices successfully, even for treating heavily calcified lesions. However, routine use of atheroablative devices is not always beneficial during percutaneous coronary intervention (PCI). 3 In the bare-metal stent (BMS) era, stenting and adjunctive rotational atherectomy (ROTA) of calcified and complex lesions was reported to have a high success rate, but also a probable incidence of angiographic restenosis. 4 In the drug-eluting stent (DES) era, ROTA is still required in a minority of patients to facilitate successful treatment, particularly of hard lesions, in which the rough surface and low compliance interferes with suitable device deployment and optimal stent expansion. Although ROTA is indicated in such cases, it is unclear whether the additional treatment with DES results in a comparable clinical outcome to patients treated with BMS.
In the present study, we assessed the clinical outcomes of PCI for calcified lesions using sirolimus-eluting stents (SES) after ROTA (ROTA-SES).
Methods

Patient Population
This study was an observational analysis in a community hospital (Tsuchiya General Hospital, Hiroshima, Japan; Patients treated with SES were compared with a historical group of 1,123 consecutive patients treated with BMS from April 2000 to December 2003. Patients with a second or further registration, stent diameter ≥4 mm or ≤2.25 mm, undergoing PCI for in-stent restenosis, or with AMI were excluded from the control group.
We compared the 2-year clinical outcomes of patients treated with SES or BMS. Most subjects were residents of Hiroshima Prefecture, a genetically representative cohort of the Japanese population. Written informed consent was given by each patient.
(Y.H.), based on the morphology of the lesions. ROTA was indicated for hard lesions, which were defined as showing thick calcification on angiography or widespread superficial calcification on intravascular ultrasound (IVUS, Boston Scientific) that would interfere with device deployment or adequate balloon expansion at the site. Individual burring runs were performed with burrs at a speed of 190,000-210,000 rpm. A procedure was considered successful when the residual diameter of stenosis was <20% in the absence of major periprocedural complications (death, MI or emergency bypass surgery). Periprocedural antithrombotic medications were used according to the operator's discretion and current recommendations. Antiplatelet treatment was prescribed according to current standards of treatment, including lifelong aspirin for all patients, 1 month of ticlopidine (200 mg/day) for patients treated with BMS, and at least 6 months of ticlopidine for patients treated with SES.
Coronary Lesion Analysis
Lesions were classified according to the modified American Heart Association/American College of Cardiology (AHA/ ACC) classification. 5, 6 Lesions were measured on angiograms by experienced cardiologists. Lesion length, reference vessel diameter, minimal lumen diameter (MLD), and percent diameter stenosis were measured using a computerized, automated, edge-detection algorithm (Philips Medical System, Best, The Netherlands). 7
Endpoints and Follow-up
The primary endpoint of the study was the occurrence of major adverse cardiac events (MACE), defined as cardiac death, non-fatal Q-wave MI, or target lesion revascularization (TLR) after the index PCI. The secondary endpoint consisted of all-cause mortality, stent thrombosis and each component of MACE.
During follow-up, death was regarded as cardiac in origin unless an obvious non-cardiac cause could be identified.
Quantitative coronary angiography (QCA) data at followup were obtained from the scheduled angiogram at 6-12 months after the index PCI or at an ischemic event before scheduled angiography. The second or further follow-up angiograms were not included in the QCA analysis.
Binary restenosis was considered as stenosis >50% diameter in the stented lesion. Late luminal loss was defined as post-procedural MLD minus MLD at follow-up measured by QCA. TLR was defined as any repeat PCI or surgical bypass of the original target lesion. A target lesion was considered to be the area covered by the stent plus a 5-mm margin proximal and distal to the edges of the implanted stent. MI during follow-up was diagnosed as serum creatinine kinase level >3-fold the upper limit of normal. The Academic Research Consortium (ARC) definition of stent thrombosis was used as the endpoint for stent thrombosis. 8 All patients treated with SES were participants in the j-Cypher Registry and follow-up information was obtained from the data management center of the registry. 9 In the control group, follow-up information was obtained from medical records or by questionnaires obtained from local physicians. The first event to arise in any specific patient was noted as the primary event.
Statistical Analysis
For continuous variables, data are presented as mean ± SD and compared by Student's t-test. For categorical numbers, data are shown as number and percentage, and were compared by the χ2 test. The cumulative incidence of adverse events was estimated according to the Kaplan-Meier method, and curves were compared using a log-rank test. A multivariate Cox proportional hazard model was used to assess the effect of SES on adverse events over time after the index PCI, as compared with BMS. Confounders included for the adjustment were age, gender, diabetes, history of MI, and renal failure [0, estimated glomerular filtration rate (eGFR) 10 ≥60 ml · min -1 · 1.73 m −2 ; 1, eGFR 30-59; 2, eGFR <30; 3, dialysis). P<0.05 was considered significant. All statistical analyses were performed using JMP for Windows, version 5.1 (SAS Institute, Cary, NC, USA).
Results
Patients, Lesions and Procedures
Characteristics of the patients with and without ROTA are shown in Table 1 . Patients treated with ROTA were older (70.3±10.5 vs 68.7±10.5 years, P=0.025), had more extensive coronary artery disease (number of diseased vessels 2.0±0.8 vs 1.8±0.8, P<0.0001), and higher prevalence of renal failure on dialysis (35.9% vs 8.3%, P<0.0001) and insulin-requiring diabetes (12.1% vs 5.5%, P=0.0003). When patients were divided according to stent type ( Table 2) , patients treated with SES had a higher prevalence of insulin-requiring diabetes and lower prevalence of prior MI, with or without ROTA. Table 3 shows the procedural and lesion characteristics. The prevalence of complex lesions (AHA B2/C) and severe calcification on angiography was high in patients treated with ROTA. The average final burrto-artery ratio was 0.67±0.17, and the final burr size was smaller in the ROTA-SES group than in the ROTA-BMS group. Stent size was smaller and longer in the SES group than in the BMS group, with or without ROTA. Final balloon pressure was higher in the SES group than in the BMS group, with or without ROTA. Values are mean ± SD or percent. BMS, bare metal stent; SES, sirolimus-eluting stent. Other abbreviations see Table 1 . Values are percent or mean ± SD. *Angiographic evaluation. Abbreviations see Tables 1,2 .
QCA Analysis
Baseline, post-procedural, and follow-up measurements are presented in Table 4 . In patients treated without ROTA, the post-procedural MLD was smaller in the SES group than in the BMS group. In patients treated with ROTA, the post-procedural MLD was comparable in both groups. Angiographic follow-up was obtained in 73% of the SES group and 60% of the BMS group (P<0.0001). Median follow-up period of angiography was 189 (161-222) days for the BMS group and 208 (181-258) days for the SES group (P<0.0001). In patients treated without ROTA, the incidence of binary restenosis per lesion was 24.9% for the BMS group and 8.2% for the SES group (P<0.0001). In patients treated with ROTA, the incidence of binary restenosis per lesion was 41.4% for the BMS group and 23.2% for the SES group (P=0.0014). Among the heavily calcified lesions, the incidence of binary restenosis per lesion was 14.6% for the non-ROTA-BMS group and 22.2% for the non-ROTA-SES group (P=0.43), and 40.8% for the ROTA-BMS group and 24.5% for the ROTA-SES group (P=0.062).
Outcome Data
The median follow-up period was 730 days (interquartile range: 382-1,279 days). Angiographic follow-up was performed in 73% of the SES group and 60% of the BMS group (P<0.0001). The patients who did not undergo angiographic follow-up refused repeat catheterization because they were free from angina pectoris.
The number of outcome events and estimated event rates at 30 days, and 1 and 2 years, by Kaplan-Meier method are summarized in Table 5 . At 2 years, the rate of composite cardiac events (cardiac death, Q-wave MI or TLR) was 28.3% in the BMS group and 15.2% in the SES group (P< 0.0001) in patients without ROTA, and 43.1% in the BMS group and 30.1% in the SES group of patients with ROTA (P=0.028). The crude risk reduction in 2-year MACE with SES compared with BMS was 46.3% in the non-ROTA group and 30.2% in the ROTA group. The difference between the BMS and SES groups was mainly derived from the TLR rates (24.8% in non-ROTA-BMS and 12.3% in non-ROTA-SES, P<0.0001; 39.1% in ROTA-BMS and 25.0% in ROTA-SES, P=0.022). The crude risk reduction in 2-year TLR was 50.4% in the non-ROTA group and 36.1% in the ROTA group. After adjusting for confounders of age, gender, prior MI, diabetes and renal failure, the use of SES after ROTA was associated with a reduction in MACE and TLR, with a similar hazard ratio (HR) to the non-ROTA group (0.67 vs 0.67 in MACE and 0.65 vs 0.64 in TLR) ( Table 6) . No difference was apparent between the BMS and SES group for death, cardiac death, MI or stent thrombosis in both the unadjusted and adjusted analysis, with or without ROTA (Tables 5,6 ). Of note, the occurrence of TLR after the index PCI in the BMS patients was similar at 1-2 years (23.4-24.8% in the non-ROTA group and 38.2-39.1% in the ROTA group), whereas in the SES group the TLR rate slowly increased over the same time period (8.3-12 .3% in the non-ROTA group and 21.2-25.0% in the ROTA group).
Subgroup Analysis
Subgroup analysis of TLR according to dialysis is presented in Figure 2 . There was no difference in the patient characteristics of the ROTA and non-ROTA groups of dialysis patients. In non-dialysis patients (Panel A), Kaplan-Meier analysis showed a remarkable reduction in 2-year TLR rate by SES, in both the non-ROTA (24% vs 12%, P<0.0001) and ROTA (38% vs 17%, P=0.0011) groups, with a similar crude HR of 0.62 and 0.60, respectively. In dialysis patients (Panel B), those treated with non-ROTA-SES showed a trend toward a lower incidence of TLR in the SES group compared with the non-ROTA-BMS group; however, the difference was not significant (33% vs 18%, P=0.14). Dialysis patients treated with ROTA-SES had a similarly high 2-year TLR rate to that in the ROTA-BMS group (40% vs 36%, P=0.55)
Discussion
The primary finding of this study was that treatment with ROTA-SES was associated with a moderate reduction in MACE, mainly derived from a lower incidence of TLR, compared with patients undergoing ROTA-BMS. Among non-dialysis patients, the effectiveness of ROTA-SES for reducing TLR compared with ROTA-BMS was similar to that of non-ROTA-SES compared with non-ROTA-BMS. This suggests that ROTA followed by SES placement may optimize PCI, even in selected patients with hard lesions. Among dialysis patients, on the other hand, treatment with ROTA-SES was associated with a similarly high incidence of TLR to that with ROTA-BMS, which suggests a limited effects of SES in this particular population.
We have previously reported that the TLR rate after treatment with SES is relatively high in dialysis patients. 11 Coronary plaques in dialysis patients are characterized by increased medial thickness and marked calcification, which are potential risks for suboptimal stent expansion. 12 According to IVUS analysis, under-expansion seems to be the most common mechanism of SES restenosis. 13 In the present study, we assessed the effects of prior preparation of hard lesions by ROTA before SES deployment, on the assumption that complex morphology of coronary artery lesions, especially marked calcification, may be related to the limited effect of SES.
In the present study, the crude rate of 2-year TLR in the ROTA-SES group was 25.0%, which represented a moderate reduction compared with the 39.1% in the ROTA-BMS group. After adjusting for confounders of age, sex, diabetes mellitus, prior MI, and renal failure, multivariate analysis showed that the use of SES after lesion preparation by ROTA had a similar reduction in TLR as in the non-ROTA population, which indicates that the effect of SES is similar in patients with and without ROTA. Thus, treatment with ROTA before SES placement appears to be a suitable method for hard lesions that may not be adequately treated with angioplasty and stenting only, as reported in the DES era. 14, 15 On the other hand, subgroup analysis of dialysis patients showed that the reduction in TLR by SES, as compared with BMS, was attenuated in both the non-ROTA and ROTA groups, which suggests that the limited effect of SES is possibly specific to dialysis patients. In our population, complex and heavily calcified lesions in dialysis patients were still the limiting factor for SES, even after lesion preparation with ROTA. Dialysis patients showed a heterogeneous outcome to treatment with SES. Some studies have shown the efficacy of PCI using DES in dialysis patients, with a similar reduction in repeat revascularization as in non-dialysis patients. [16] [17] [18] However, recent reports from Japan have shown that the TLR rate is similar between SES and BMS groups of dialysis patients. 11, 19, 20 As discussed in those reports, a higher rate of angiographic follow-up may explain the increasing rate of TLR in Japan. Furthermore, different percentages of patients with complex and highly calcified lesions may contribute to the relatively high rate of TLR. The delivery of coronary stents through the rough surface of a calcified coronary artery lumen possibly strips out the polymer and drug of the SES. 21 The recent imaging modality of optical coherence tomography has detected stent strut malapposition, which is a potential risk factor for restenosis or thrombosis because of the increased activity of fibrin and platelets, 22 after treatment of heavily calcified lesions, despite the use of high-pressure dilatation or ROTA. 23 Changes in strategy from the BMS to the SES era, including smaller diameter and longer stents, and smaller burr size in the ROTA-SES group, may be related to the poor outcome after ROTA-SES in the dialysis patients.
Heavily calcified lesions showed a relatively high rate of restenosis after treatment with a SES with or without ROTA (24.5% and 22.2%, respectively). However, cautious interpretation is required because of the biased quantification for calcification and the confounding interaction between calcification and dialysis. From our results, dialysis seems to be the specific factor involved in the limited effect of SES. Among studies of the effect of DES in dialysis patients, those in Japan have included only SES, 11, 19, 20 whereas other studies have included SES and paclitaxel-eluting stents. [16] [17] [18] The different results from these studies may reflect a class effect between the DES used in dialysis patients. In our study, there was no increase in the occurrence of thrombosis or MACE after ROTA-SES as compared with ROTA-BMS. Renal failure, which is commonly related to the high prevalence of coronary artery calcification, has been associated with thrombotic events after using DES. 24, 25 Heavily calcified lesions sometimes lead to suboptimal expansion and strut malapposition, which are potential risk factors for stent thrombosis after DES use, 13, 26 even after ROTA and high-pressure balloon dilatation. 23 Patients with calcified lesions that require ROTA, but who may not have been adequately treated with angioplasty, have a potentially high risk of stent thrombosis, so careful long-term monitoring is required.
The time course of late luminal loss after coronary stenting seems to differ between BMS and DES. 27, 28 Serial quantitative IVUS in 23 event-free patients after SES implantation has led to speculation that late, chronic peri-arterial responses caused by persistent tissue shrinkage may evolve for up to 4 years. 29 In contrast, another previous study of consecutive patients treated with SES showed no evidence of such a late, restenotic "catch-up" phenomenon. 30 Our study showed a slowly increasing occurrence of TLR at 1-2 years after the index PCI in the SES group. However, the number of events after 1 year was too small to analyze sta-tistically. Further large-scale studies or serial angiographic data are required to assess the late "catch-up" issue after SES implantation.
Study Limitations
First, this was a single-center observational study, not a randomized control study. Although multivariate analysis showed adjusted data for established confounders, our results may not be precise because of population bias or hidden confounders. Second, ROTA was indicated for hard lesions defined as angiographic thick calcification or a wide range of IVUS-guided superficial calcification. There might be an eligibility bias because of the difficulty in accurately indicating ROTA in a scientific way. However, treatment decisions were made by a single experienced physician (Y.H.) at our institution, so the ROTA-BMS and ROTA-SES groups were fairly well-balanced. Third, not all the patients underwent follow-up angiography (65.5% of overall cohort). Moreover, our initial protocol of detecting TLR included clinically and angiographically driven events. This may explain the relatively high TLR rate in the present study compared with that in previous studies that included only clinically driven events. 31 Finally, cautious interpretation is required in generalizing our results because the study population was relatively small and there was a wide range of comorbidities and lesion complexities that influenced outcomes. However, the population did consist of consecutive patients and as such does reflect the real clinical situation.
Conclusion
The use of SES after lesion preparation by ROTA led to a significant risk reduction for TLR as compared with the use of BMS after ROTA. The degree of risk reduction was comparable with that in the non-ROTA population. Thus, treatment with ROTA before SES placement appears to be an appropriate method for hard lesions that may not be adequately prepared with angioplasty alone in the DES era. However, SES had a limited effect in dialysis patients, even after lesion preparation with ROTA.
